PROCEPT BioRobotics stock fell 1.74 percent on October 6

Published on 10/07/2026 at 03:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

PROCEPT BioRobotics stock posted USD 94.5 million in Q2 2026 revenue, up 19.3 percent year over year. Analysts set a Hold consensus and USD 25.09 target across 15 ratings.

PRCT, US74276L1052, Illustration mit AI erstellt.

PROCEPT BioRobotics stock (ISIN US74276L1052) was last at USD 17.51 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 1.74 percent. The price stood 5.1 percent above the 52-week low of USD 16.66, keeping the stock close to the bottom of its USD 16.66 to USD 38.11 yearly range.

Revenue grows while losses persist

For Q2 2026, PROCEPT BioRobotics reported revenue of USD 94.5 million, up 19.3 percent from the same quarter a year earlier, according to MarketBeat. The quarter also produced a reported EPS loss of USD 0.47, which missed the USD 0.46 consensus loss by USD 0.01.

The revenue comparison shows that demand continued to expand, but the earnings figure keeps profitability at the center of the stock story. PROCEPT BioRobotics develops and sells the AQUABEAM Robotic System for image-guided urologic surgery, with an initial focus on benign prostatic hyperplasia, according to PROCEPT BioRobotics.

Legal scrutiny adds a risk factor

A securities lawsuit announced on October 1, 2026 alleges that a discount program encouraged bulk orders above underlying demand and inflated reported U.S. handpiece sales, as PR Newswire reported. The allegations focus on disclosure and demand quality rather than the Q2 revenue total itself.

Governance also changed on October 2, 2026. An SEC Form 8-K reported that PROCEPT BioRobotics expanded its board from nine to ten members and appointed cardiac surgeon Dr. Michael Mack as an independent Class II director, according to StockTitan.

Analysts price in a recovery

MarketBeat reports a Hold consensus from 15 analysts and an average price target of USD 25.09. The target lies 43.3 percent above the USD 17.51 price on October 6, 2026, a gap that implies expectations for a recovery despite the recent legal overhang and the quarterly loss.

Stock stays near yearly low

At USD 17.51 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, PROCEPT BioRobotics stock was 5.1 percent above its 52-week low and had a market capitalization of USD 996.6 million.